Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096508 | 1.00 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL2329376 | 1.00 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL5691699 | 0.91 | CA1 (0.46) | CA1CA2CA7CTSKATM | |
| SCHEMBL25319084 | 0.89 | CA1 (0.41) | CA1CA2CA7CTSKATM | |
| SCHEMBL25319090 | 0.89 | CA1 (0.41) | CA1CA2CA7CTSKATM | |
| SCHEMBL20276859 | 0.87 | CTSK (0.47) | CA1CA2CA7CTSKATM | |
| SCHEMBL4671387 | 0.87 | CYP2D6 (0.45) | CA1CA2CA7CTSKATM | |
| SCHEMBL13964494 | 0.87 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL15376153 | 0.87 | CTSK (0.47) | CA1CA2CA7CTSKATM | |
| SCHEMBL2104058 | 0.87 | CYP2D6 (0.45) | CA1CA2CA7CTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC | 2009-12-10 | — | — | US | disclosed |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070197640-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| EP-1742907-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INCORPORATED | 2006-05-04 | — | — | US | disclosed |
| WO-2005107762-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197640-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | CA1 1998/4885CA2 798/4885CA7 908/4885 |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | KIF5B, KIF18A, KIF2C | CA1 4370/4885CA2 2832/4885CA7 3872/4885 |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | CA1 559/4885CA2 2554/4885CA7 4584/4885 |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | KIF5B, KIF2C, PLK1 | CA1 2913/4885CA2 2107/4885CA7 3025/4885 |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | CA1 2913/4885CA2 2107/4885CA7 3025/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.